MCE products for research use only. We do not sell to patients.

Sugemalimab

MCE China：Sugemalimab

Brand：MedChemExpress (MCE)

Cat. No.HY-P99114

CAS：2256084-03-2

Purity：98.3%

Storage：Please store the product under the recommended conditions in the Certificate of Analysis.

Description：Sugemalimab is a fully human, full length, anti-programmed death ligand 1 (PD-L1) immunoglobulin G4 (IgG4) monoclonal antibody (mAb). Sugemalimab shows anticancer activities and can be used for non-small cell lung cancer research.

In Vitro：Sugemalimab (CS1001) specifically binds to PD-L1, competitively blocks the binding of human PD-L1 with PD-1 and CD80, and effectively induces CD4+?T lymphocyte proliferation and enhances the production of interferon-γ and interleukin-2[2]. Sugemalimab employs IgG4 isotype and lacks antibody-dependent cellular mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC)[2].

In Vivo：Sugemalimab (CS1001) signifcantly inhibits tumor growth in the subcutaneous MC38-hPD-L1 murine colon carcinoma (murine MC38 cells expressing human PD-L1) in human PD-1 knock-in mouse model[2]. Sugemalimab not only enhances the cytotoxic T cell/regulatory T cell ratio, but also significantly upregulates M1 macrophage and down-regulated MDSC (myeloid-derived suppressor cells) population in D-1/PD-L1 dual knock-in mice implanted with MC38-hPD-L1 tumor[2].

IC50 & Target：PD-L1[1] In Vitro Sugemalimab (CS1001) specifically binds to PD-L1, competitively blocks the binding of human PD-L1 with PD-1 and CD80, and effectively induces CD4+?T lymphocyte proliferation and enhances the production of interferon-γ and interleukin-2[2]. Sugemalimab employs IgG4 isotype and lacks antibody-dependent cellular mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC)[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Sugemalimab Related Antibodies

Species：Human

Isotype：Human IgG4 lambda

Hot selling product：Ammonium glycyrrhizinate  | Larotrectinib sulfate  | NH2-UAMC1110 (TFA)  | Cysteamine (hydrochloride)  | APF  | Psicofuranine  | Sulfadiazine  | N-tert-Butyl-α-phenylnitrone  | Periplogenin  | EAI053

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides

References：

[1]. Dhillon S, et al. Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.  [Content Brief]

[2]. Zhang J, et al. The preclinical characterization of CS1001, an anti-PD-L1 IgG4 monoclonal antibody and its activity beyond T cell regulation. Cancer Research, 2020, 80(16_Supplement): 3260-3260.